Diversified Trust Co has recently reported an increase in its Blueprint Medicines Co. holdings by 45.7% during the first quarter, according to its latest SEC filing. The fund saw a rise of 3,405 shares bringing its total to 10,849 shares with a value of $488,000. This development has sparked investor interest in Blueprint Medicines Corporation – a precision therapy company that develops medicines specifically targeted at genomically defined cancers and blood disorders.
The biotechnology company’s most recent earnings showed a positive outcome compared to estimates from analysts. According to reports obtained from Blueprint Medicines’ quarterly earnings data released on May 4th, they posted ($2.15) earnings per share for the quarter, beating analyst predictions of ($2.66) by $0.51 cents per share.
Blueprint Medicines’ revenue for the quarter totaled $63.29 million compared to estimates of $41.85 million by analysts – indicating a 0.9% increase in revenue from the previous year’s results for the same period.
The drop experienced over time by Blueprint Medicines is as a result of negative net margins reaching up to 284.02%, and return on equity dropping as low as -100.31%. It is welcomed news that their current EPS for this fiscal year stands at -9.55 due to the positive results recorded earlier.
As part of its business strategy, Blueprint Medicines has developed some promising drugs which have attracted investor confidence such as AYVAKIT—a drug created to cure systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263—an orally available KIT inhibitor designed to cure indolent SM and other mast cell disorders; and Fisogatinib – another drug targeting cancer patients specifically.
In conclusion, investor interest seems well placed given that Diversified Trust Co.’s increased holdings in Blueprint Medicines have brought the biotech company further positive attention. With its innovative drugs designed for genomically-defined cancers, it’s no surprise that Blueprint Medicines is becoming increasingly popular with new investors.
[bs_slider_forecast ticker=”BPMC”]
Blueprint Medicines Sees Surge in Institutional Investors and Positive Analyst Reviews
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”BPMC” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]Blueprint Medicines Sees Increase in Institutional Investors and Positive Analyst Reports
Precision therapy company, Blueprint Medicines Corporation, has seen an increase in institutional investors and positive analyst reports. Van ECK Associates Corp raised its holdings in the company by 51.2% during the fourth quarter, increasing its value by $43,000 after purchasing an additional 334 shares. Lazard Asset Management LLC purchased a new position in the business worth around $57,000. Quantbot Technologies LP made a similar move buying shares worth approximately $95,000. Affinity Asset Advisors LLC also invested in Blueprint Medicines during the first quarter with a total amount of $127,000 spent on shares. Finally, Golden State Equity Partners purchased a new position in the first quarter for $201k.
Despite a high degree of interest from potential investors, Blueprint Medicines stock has had its fair share of ups and downs over the last twelve months with values ranging between its 12-month low of $37.82 and high of $79.40. It currently has a market capitalization of around $3.86 billion and debt-to-equity ratio of 0.29.
The company specializes in developing medicines for genomically defined cancers and blood disorders both within the United States and internationally . AYVAKIT is one such medicine developed for at systemic mastocytosis (SM) as well as gastrointestinal stromal tumors; BLU-263 is another key product that is orally available and can be used to treat indolent SM along with other mast cell disorders.
Recent research firm reports have been relatively positive towards Blueprint Medicine Corp with firms such as HC Wainwright increasing their price target on shares from to around $85 per share whilst Stifel Nicolaus upped their target price from $80 per share to an upper limit of$84 per share.Results like this are good indicators for prospective investors looking to get involved with the company.
One key detail was disclosed by the SEC after transactions by the corporation’s insider, Percy H. Carter had sold a total of 2,307 shares valued at over $120k. Despite this sale, Carter still owns a significant portion of Blueprint Medicines Corporation shares.
In conclusion, Blueprint Medicines Corporation continues to gain ground with investors and analysts whilst also receiving positive reviews on several products from its research team. While investments in this company should be approached with caution due to market fluctuation,it is clear that there is plenty of interest from those who follow trends in precision therapy.
